Advertisement
U.S. Markets close in 2 hrs 11 mins

  • S&P 500

    5,520.89
    -8.04 (-0.15%)
    ?

  • Dow 30

    40,869.84
    -67.09 (-0.16%)
    ?

  • Nasdaq

    17,140.26
    +3.96 (+0.02%)
    ?

  • Russell 2000

    2,149.86
    +0.64 (+0.03%)
    ?

  • Crude Oil

    69.48
    -0.86 (-1.22%)
    ?

  • Gold

    2,525.60
    +2.60 (+0.10%)
    ?

  • Silver

    28.53
    +0.19 (+0.66%)
    ?

  • EUR/USD

    1.1078
    +0.0031 (+0.2769%)
    ?

  • 10-Yr Bond

    3.7800
    -0.0640 (-1.66%)
    ?

  • Vix

    20.96
    +0.24 (+1.16%)
    ?

  • GBP/USD

    1.3138
    +0.0025 (+0.1918%)
    ?

  • USD/JPY

    144.0310
    -1.3770 (-0.9470%)
    ?

  • BTC-USD

    57,988.48
    +72.00 (+0.12%)
    ?

  • CMC Crypto 200

    1,308.28
    0.00 (0.00%)
    ?

  • FTSE 100

    8,269.60
    -28.86 (-0.35%)
    ?

  • Nikkei 225

    37,047.61
    -1,638.70 (-4.24%)
    ?

Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024

ACCESSWIRE· Aytu BioPharma, Inc.
Aytu BioPharma, Inc.
2 min read
In this article:

DENVER, CO / ACCESSWIRE / August 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq: AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will participate in a webcasted presentation and host one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Conference, taking place virtually on Wednesday, August 14, 2024, and Thursday, August 15, 2024.

Webcast
The webcasted fireside chat will take place at 12:15 p.m. Eastern time on Thursday, August 15, 2024. The webcast can be accessed by visiting the investor relations section of the Company's website at https://investors.aytubio.com or directly here. The webcast will also be available for replay following the event.

1x1 Meetings
Management will also be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact your Sidoti representative or the Company's investor relations team at [email protected].

About Aytu BioPharma, Inc.
Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT? (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT? (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal? ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor? and Tri-Vi-Flor?, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.

Contacts for Investors
Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]

Robert Blum or Roger Weiss
Lytham Partners
[email protected]

SOURCE: Aytu BioPharma, Inc.



View the original press release on accesswire.com

Advertisement